Related Experiment Videos
Response of tumors to biologic modifiers and chemotherapeutic agents
Abstract:
The use of the FANFT model has facilitated clinical trials which are now beginning to have an impact on the therapy of human bladder tumors. We studied C. parvum and Glucan immunotherapy of FANFT tumors, and demonstrated the enhancement of tumor growth following Glucan administration. Weekly injections of cyclophosphamide (CY) retarded tumor growth and increased survival. Combining C. parvum or Glucan with CY resulted in greater tumor growth inhibition than CY alone. Our data support the concept that the therapeutic effectiveness of CY can be improved by biologic modifiers that alter its rate of activation.
Insights
This study investigated immunotherapy for bladder tumors using the FANFT model. Combining cyclophosphamide (CY) with C. parvum or Glucan enhanced tumor growth inhibition more than CY alone.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- The FANFT model is crucial for advancing clinical trials in human bladder tumor therapy.
- Understanding the interplay between immunotherapy and chemotherapy is essential for optimizing cancer treatment.
Purpose of the Study:
- To investigate the effects of C. parvum and Glucan immunotherapy on FANFT-induced bladder tumors.
- To evaluate the efficacy of combining these immunotherapies with cyclophosphamide (CY).
Main Methods:
- Utilized the FANFT mouse model for bladder tumor studies.
- Administered C. parvum and Glucan immunotherapy, with and without cyclophosphamide (CY).
- Monitored tumor growth and animal survival rates.
Main Results:
- Glucan administration alone enhanced FANFT tumor growth.
- Cyclophosphamide (CY) treatment alone inhibited tumor growth and increased survival.
- Combination therapy of CY with C. parvum or Glucan demonstrated superior tumor growth inhibition compared to CY alone.
Conclusions:
- Biologic modifiers can potentially improve the therapeutic effectiveness of cyclophosphamide (CY).
- Further research into combining immunotherapy with chemotherapy holds promise for bladder cancer treatment.